MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate at the 27th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Present at the TD Cowen 44th Annual Health Care Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Reports Third Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Host CYB003 Topline Depression Study Review and R&D Briefing on November 30, 2023, in New York City
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Reports Second Quarter Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Closing of Offering of Units Led by One of the Company’s Largest Institutional Shareholders
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces up to US$64 Million Offering of Units
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin to Participate at the 2023 Milken Institute Future of Health Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Provides Corporate Update and Highlights Key Upcoming Milestones Across its Development Pipeline
From Cybin Inc.
Via Business Wire
Tickers CYBN
News headline image
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story